+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Radiation-Induced Myelosuppression Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2027-2032)

  • PDF Icon

    Report

  • 180 Pages
  • November 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6294636
The radiation-induced myelosuppression treatment market is estimated to be valued at USD 1.89 billion in 2026 and is projected to reach USD 2.75 billion by 2032, growing at a CAGR of 6.43% during the forecast period (2027-2032). This report is Segmented by Indication (Neutropenia, Anemia, Thrombocytopenia and Pancytopenia), Drug Class (Growth Factors, and More), Route of Administration (Injectable and Oral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Radiation-Induced Myelosuppression Treatment Market Trends and Insights

Rising Cancer Radiotherapy Utilization and Treatment Intensity

Radiotherapy access is expanding, which increases the number of patients who may need management for treatment-related myelosuppression. The International Atomic Energy Agency supported Mongolia in preparing a EUR 61 million investment proposal in 2025 to expand and decentralize cancer services. The agency reported that 40% of newly diagnosed patients there received radiotherapy even though 50% to 60% required it, showing the remaining access gap. IHH Healthcare invested in TibaRay in January 2026 to gain access to FLASH radiotherapy technology for its Asian hospital network. Higher-precision treatment methods, including stereotactic body radiotherapy and FLASH radiotherapy, do not eliminate radiation exposure to hematopoietic tissue. The radiation-induced myelosuppression treatment market therefore remains linked to the growing use of advanced radiation services, especially as particle beam and proton therapy capacity expands in Asia-Pacific.

Government Stockpiling and Radiological Emergency Preparedness

Government procurement of radiation countermeasures follows preparedness priorities rather than normal oncology purchasing patterns. BARDA invested USD 1.04 billion in chemical, biological, radiological, and nuclear medical countermeasures during fiscal year 2025. ASPR's multiyear budget released in July 2026 allocated USD 37.1 billion to BARDA for fiscal years 2025 through 2029. The European Commission authorized IMREPLYS, a sargramostim product from Partner Therapeutics, for treatment of hematopoietic acute radiation syndrome in September 2025. That authorization allows procurement for stockpiling across EU and EEA markets covered by the approval. ASPR expects up to 11 additional medical countermeasure products to transition into the Strategic National Stockpile by fiscal year 2029, supporting a larger procurement pathway for products that meet government requirements.

High Cost and Biosimilar Price Erosion

Biosimilar competition is reducing selling prices in the G-CSF category without a matching increase in volume. In the United States, the commercial setting for pegfilgrastim has become increasingly price-sensitive as several biosimilars compete for formulary placement. This pressure affects originators and biosimilar suppliers because the treatment choice is often driven by reimbursement, contracting, and hospital purchasing decisions. The resulting revenue base depends more on adoption in new indications and geographies than on higher prices. For the radiation-induced myelosuppression treatment market, this makes a broad regulatory portfolio more valuable than a premium profile based only on brand recognition. It also limits revenue predictability for suppliers whose portfolios are concentrated in mature injectable growth factors.

Other drivers and restraints analyzed in the detailed report include:

  1. Expansion of Oncology and Hematology Supportive-Care Infrastructure
  2. Multilineage Recovery Demand Beyond Neutrophil Support
  3. Animal-Rule Evidence and Regionally Variable Approval Requirements

Segment Analysis

Neutropenia accounted for 46.32% of revenue in 2026, making it the largest indication within the radiation-induced myelosuppression treatment market. Its position reflects its high incidence in clinical radiotherapy and hematopoietic acute radiation syndrome settings. G-CSF treatment remains embedded in prophylactic care practices for patients at risk of neutrophil depletion. The HHS Radiation Emergency Medical Management resource listed 13 myeloid cytokine products with approval for acute exposure to myelosuppressive radiation as of May 2026. This broad group gives hospital pharmacies several product options and reinforces the established role of growth factors in emergency readiness. Anemia is generally managed with erythropoiesis-stimulating agents and iron supplementation, but slower response kinetics limit the use of erythropoiesis-stimulating agents in immediate emergency care. Pancytopenia creates a more complex need because patients may require support for neutrophils, platelets, and red blood cells at the same time. Sargramostim is relevant in this setting because of its multilineage activity.

Thrombocytopenia is forecast to record a 6.89% CAGR through 2032, the fastest rate among indications in the radiation-induced myelosuppression treatment market. Its growth depends on more evidence for romiplostim and other thrombopoietin receptor agonists in cancer therapy and radiation-related settings. A Phase II study of romiplostim N01 in leukemia patients with cancer treatment-induced thrombocytopenia enrolled 97 patients after beginning in February 2025. Interim findings showed that 46.9% of enrolled patients achieved platelet counts above 50×10⁹/L within 2 weeks. The evidence is important because radiation-induced thrombocytopenia is not the same as immune thrombocytopenia, the primary approved use for thrombopoietin receptor agonists. Results from immune thrombocytopenia studies cannot simply be applied to radiation-related disease. Manufacturers that fund studies in radiation-specific and cancer therapy-specific populations may be better positioned as clinical evidence develops. The need for this evidence also limits how quickly the indication can move into standard treatment protocols.

Growth factors held 42.75% of revenue in 2026 and remain the largest drug class in the radiation-induced myelosuppression treatment industry. Their leading role comes from routine prophylactic use in oncology care and the established place of myeloid cytokines in emergency response. The class includes short-acting and long-acting products that are familiar to cancer centers and stockpiling programs. As biosimilar choices expand, lower acquisition costs can extend access in health systems that would otherwise have limited use of supportive biologics. The class also benefits from a well-developed distribution base across hospital pharmacies, infusion centers, and government supply systems. However, its market position does not prevent margin pressure because products with similar mechanisms often compete through pricing and contracting. The availability of several FDA-approved H-ARS products keeps the class important, while also increasing choice among suppliers.

Thrombopoietic agents are forecast to grow at a 7.27% CAGR through 2032, making them the fastest-growing drug class in the radiation-induced myelosuppression treatment market. Their growth is supported by the clinical need to prevent or shorten platelet depletion, which can lead to treatment delays and transfusions. In the RECITE Phase III study, romiplostim produced a platelet nadir of 87×10⁹/L compared with 58×10⁹/L for placebo and reduced the time to first platelet response from 2.1 weeks to 1.1 weeks. Erythropoiesis-stimulating agents serve radiation-induced anemia but generally require weeks before meaningful hemoglobin improvement. Iron supplements have a complementary role where iron deficiency complicates anemia during extended radiotherapy courses. The other category includes oral small molecules, cell-based therapies such as PLX-R18, and CDK4/6 inhibitors at preclinical or early clinical stages. New drug classes still require evidence that meets the FDA Animal Rule for H-ARS entry, which shapes the timing and scope of competitive entry.

Complete Report Scope:

  • By Indication
    • Neutropenia
    • Anemia
    • Thrombocytopenia
    • Pancytopenia
  • By Drug Class
    • Growth Factors
    • Erythropoiesis-Stimulating Agents
    • Thrombopoietic Agents
    • Iron Supplements
    • Others
  • By Route of Administration
    • Injectable
    • Oral
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Others
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Geography Analysis

North America held 38.54% of revenue in 2026, the largest regional position in the radiation-induced myelosuppression treatment market. The region benefits from the United States Strategic National Stockpile, broad oncology supportive-care use, and mature reimbursement pathways for biosimilars. The stockpile includes Neupogen, Neulasta, Leukine, and Nplate through vendor-managed inventory arrangements that rotate products into commercial channels before expiration. BARDA's fiscal year 2025 investment of USD 1.04 billion in CBRN medical countermeasures supports continuing government demand for eligible products. The PHEMCE multiyear budget also provided USD 37.1 billion to BARDA for fiscal years 2025 through 2029. The FDA is the central regulatory influence for H-ARS approvals, while its Animal Rule directly affects candidates that cannot be tested in conventional human efficacy studies. Canada is advancing nuclear emergency preparedness, and Mexico has a more commercial pharmaceutical distribution model. The concentration of approved products brings ready access, but it also makes biosimilar price competition more visible than in other regions.

Asia-Pacific is forecast to grow at an 8.58% CAGR through 2032 as cancer infrastructure and radiation capacity expand across major health systems. Guangzhou Concord Cancer Hospital began full-scale proton therapy operations in late 2024 and treated its 1,000th proton patient in July 2026. Domestic Chinese patients represented 85% of that total, indicating the increasing local use of advanced radiation services. IHH Healthcare expanded its work with Leo Cancer Care in September 2025 for upright radiotherapy linacs and compact proton solutions across its regional network. The region's large population and rising treatment capacity provide a wider base for cytopenia management. South Korea's KIRAMS continues work on automated biological dose assessment, which can shorten triage times after a radiation incident. Japan and Australia have established supportive-care markets and biosimilar reimbursement systems. India and Southeast Asia are adding hospital oncology capacity and contributing to the regional increase in patient volume.

Europe is the second-largest revenue region, with Germany, the United Kingdom, and France forming its primary markets. The European Commission's September 2025 authorization of IMREPLYS was the first approval for an H-ARS treatment in Europe and provides a basis for procurement across countries covered by the authorization. The EMA's regulatory influence differs from the FDA pathway, which makes regional evidence planning important for developers. In the Middle East and Africa, GCC countries are investing in cancer treatment capacity while South Africa remains an important commercial center in sub-Saharan Africa. The IAEA's 12-center Rays of Hope Anchor Center network includes sites in African and Asia-Pacific locations, expanding the infrastructure required for radiotherapy access. Brazil leads South American demand, while Argentina is a secondary treatment center. A 2025 systematic review found that stockpiling recommendations for radiological and nuclear emergencies are less mature outside the United States. This gap limits current demand in some countries but leaves room for future preparedness policies and organized procurement.



List of Companies Covered in this Report:

  1. Accord BioPharma Inc.
  2. Amgen
  3. Coherus Biosciences
  4. Fresenius
  5. G1 Therapeutics Inc.
  6. Johnson & Johnson
  7. Kashiv BioSciences
  8. Lupin
  9. Novartis
  10. Partner Therapeutics, Inc.
  11. Pluri Inc.
  12. Sandoz Group
  13. Spectrum Pharmaceuticals
  14. Swedish Orphan Biovitrum
  15. Tanvex BioPharma, Inc.
  16. Teva Pharmaceutical Industries

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 Research Methodology3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Cancer Radiotherapy Utilization and Treatment Intensity
4.2.2 Government Stockpiling and Radiological-Emergency Preparedness
4.2.3 Expansion of Oncology and Hematology Supportive-Care Infrastructure
4.2.4 Multilineage Recovery Demand Beyond Neutrophil Support
4.2.5 Long-Acting and Device-Enabled Administration for Resource-Limited Response
4.2.6 Improved Biodosimetry and Radiation-Triage Protocols
4.3 Market Restraints
4.3.1 High Cost and Biosimilar Price Erosion
4.3.2 Limited Routine Patient Volume and Irregular Emergency Demand
4.3.3 Animal-Rule Evidence and Regionally Variable Approval Requirements
4.3.4 Pediatric Dose Accuracy and Device-Use Constraints
4.4 Value and Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter’s Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Buyers
4.7.3 Bargaining Power of Suppliers
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Indication
5.1.1 Neutropenia
5.1.2 Anemia
5.1.3 Thrombocytopenia
5.1.4 Pancytopenia
5.2 By Drug Class
5.2.1 Growth Factors
5.2.2 Erythropoiesis-Stimulating Agents
5.2.3 Thrombopoietic Agents
5.2.4 Iron Supplements
5.2.5 Others
5.3 By Route of Administration
5.3.1 Injectable
5.3.2 Oral
5.4 By Distribution Channel
5.4.1 Hospital Pharmacies
5.4.2 Retail Pharmacies
5.4.3 Online Pharmacies
5.4.4 Others
5.5 By Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 India
5.5.3.3 Japan
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
6.3.1 Accord BioPharma Inc.
6.3.2 Amgen Inc.
6.3.3 Coherus BioSciences, Inc.
6.3.4 Fresenius Kabi AG
6.3.5 G1 Therapeutics Inc.
6.3.6 Johnson & Johnson Inc.
6.3.7 Kashiv BioSciences
6.3.8 Lupin Limited
6.3.9 Novartis AG
6.3.10 Partner Therapeutics, Inc.
6.3.11 Pluri Inc.
6.3.12 Sandoz AG
6.3.13 Spectrum Pharmaceuticals, Inc.
6.3.14 Swedish Orphan Biovitrum AB (Sobi)
6.3.15 Tanvex BioPharma, Inc.
6.3.16 Teva Pharmaceutical Industries Ltd.
7 Market Opportunities and Future Outlook
7.1 White-Space and Unmet-Need Assessment

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Accord BioPharma Inc.
  • Amgen Inc.
  • Coherus BioSciences, Inc.
  • Fresenius Kabi AG
  • G1 Therapeutics Inc.
  • Johnson & Johnson Inc.
  • Kashiv BioSciences
  • Lupin Limited
  • Novartis AG
  • Partner Therapeutics, Inc.
  • Pluri Inc.
  • Sandoz AG
  • Spectrum Pharmaceuticals, Inc.
  • Swedish Orphan Biovitrum AB (Sobi)
  • Tanvex BioPharma, Inc.
  • Teva Pharmaceutical Industries Ltd.